IFNA1 and primary cutaneous T-cell non-Hodgkin lymphoma: Through these mechanisms, IFN-α has been used to treat cutaneous T-cell lymphoma (CTCL) and augment therapy with psoralen plus ultraviolet A (UVA) light phototherapy [36].